PIPS Key Facts
Active Substance |
- NEISSERIA MENINGITIDIS GROUP C POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN
- NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN
- NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN
- NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN
- Recombinant Neisseria meningitidis serogroup B protein 1
- Recombinant Neisseria meningitidis serogroup B protein 2
- Recombinant Neisseria meningitidis serogroup B Protein-based active substance
- Recombinant Neisseria meningitidis serogroup B protein 3
|
Invented Name
|
Not yet available
|
PIP Number |
MHRA-100851-PIP01-23 |
Pharmaceutical form(s)
|
Pharmaceutical form(s):
|
Therapeutic area
|
Therapeutic area:
|
Conditions / Indications
|
Conditions / Indications:
- Prevention of meningococcal disease (serogroups A, B, C, W and Y)
|
Route(s) of administration
|
Route(s) of administration:
|
PIP applicant
|
|
Decision Type
|
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
|
Compliance Check
|
|
Compliance Check Decision Date
|
|
Compliance Check Procedure Number
|
|